Get the Stockscreener App
8.366
4.31%
-0.374
Biohaven Ltd stock is traded at $8.366, with a volume of 1.25M.
It is down -4.31% in the last 24 hours and down -29.48% over the past month.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
See More
Previous Close:
$8.74
Open:
$8.56
24h Volume:
1.25M
Relative Volume:
0.46
Market Cap:
$1.26B
Revenue:
-
Net Income/Loss:
$-738.82M
P/E Ratio:
-1.202
EPS:
-6.9602
Net Cash Flow:
$-610.15M
1W Performance:
-12.24%
1M Performance:
-29.48%
6M Performance:
-39.13%
1Y Performance:
-73.06%
1-Day Range:
$8.28
$8.70
1-Week Range:
$8.28
$9.445
52-Week Range:
$7.48
$31.18
Biohaven Ltd Stock (BHVN) Company Profile
Name
Biohaven Ltd
Sector
Industry
Phone
203-404-0410
Address
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
8.38 | 1.31B | 0 | -738.82M | -610.15M | -6.9602 |
VRTX
Vertex Pharmaceuticals Inc
|
451.75 | 114.63B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
738.55 | 77.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
673.14 | 42.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
306.76 | 40.67B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
274.72 | 30.50B | 5.36B | 287.73M | 924.18M | 2.5229 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-06-26 | Initiated | Goldman | Buy |
| Jan-21-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Dec-03-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-26-25 | Downgrade | UBS | Buy → Neutral |
| Nov-06-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Nov-05-25 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-17-25 | Initiated | Citigroup | Buy |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| May-19-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Sep-16-24 | Initiated | Jefferies | Buy |
| Sep-04-24 | Initiated | Bernstein | Outperform |
| Jul-24-24 | Initiated | Morgan Stanley | Overweight |
| Feb-16-24 | Initiated | RBC Capital Mkts | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Dec-22-23 | Initiated | H.C. Wainwright | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Jan-24-23 | Initiated | SVB Securities | Outperform |
| Jan-04-23 | Initiated | JP Morgan | Overweight |
| Dec-02-22 | Initiated | BTIG Research | Buy |
| Oct-26-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-12-22 | Initiated | Piper Sandler | Overweight |
| Aug-19-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-08-22 | Downgrade | Wedbush | Outperform → Neutral |
| May-11-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-21 | Downgrade | UBS | Buy → Neutral |
| Aug-03-21 | Reiterated | Canaccord Genuity | Buy |
| Mar-11-21 | Initiated | UBS | Buy |
| Dec-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-17-20 | Initiated | Cowen | Outperform |
| Feb-10-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Nov-22-19 | Initiated | Wedbush | Outperform |
| Jun-25-19 | Reiterated | Canaccord Genuity | Buy |
| May-06-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-04-19 | Reiterated | Needham | Buy |
| Jul-03-18 | Reiterated | Needham | Buy |
| Jul-02-18 | Reiterated | Needham | Buy |
| Apr-05-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-22-18 | Reiterated | Canaccord Genuity | Buy |
| Dec-15-17 | Initiated | Canaccord Genuity | Buy |
| Oct-03-17 | Reiterated | Needham | Buy |
View All
Biohaven Ltd Stock (BHVN) Latest News
Biohaven Shares Drop 70%, Yet a Fund’s Fresh $6 Million Investment Hints at Possible Recovery - Bitget
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential - The Motley Fool
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential - The Motley Fool
Movement Recap: What is the long term forecast for Biohaven Ltd stockGDP Growth & Weekly High Return Stock Forecasts - baoquankhu1.vn
Biohaven shares edge higher after completing enrollment in obesity drug trial - MSN
Biohaven Ltd. (NYSE:BHVN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Biohaven’s robust cash reserves and unique degrader strategy ignite a strong value opportunity, with crucial 2026 clinical trials approaching - Bitget
Biohaven's 2026 Pivotal Trial Countdown: Can Capital Discipline Unlock a High-Risk, High-Reward Moat? - Bitget
DAFNA Capital Management Increases Biohaven Ltd. Investment in 2025News and Statistics - IndexBox
Biohaven Ltd.: Fundamental Analysis and Financial Ratings | BHVN34 | BRBHVNBDR001 - marketscreener.com
Biohaven completes enrollment in obesity drug trial By Investing.com - Investing.com India
Biohaven (NASDAQ: BHVN) director reports gifting 34,684 shares, adds family trust - Stock Titan
Risk Off: What is the long term forecast for Biohaven Ltd stock2026 Market WrapUp & Precise Swing Trade Alerts - baoquankhu1.vn
Biohaven Therapeutics discloses prodrugs of betahistine - BioWorld MedTech
Biohaven Ltd. Completes Enrollment In Phase 2 Obesity Study With Taldefgrobep Alfa - marketscreener.com
Biohaven completes enrollment in obesity drug trial - Investing.com
Biohaven stock rises as obesity trial completes enrollment - Investing.com UK
Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment - PR Newswire
Biohaven has completed enrollment for its obesity study—However, the market still hasn't factored in the potential risk of the trial not succeeding - Bitget
Precision Trading with Biohaven Ltd. (BHVN) Risk Zones - Stock Traders Daily
Pullback Watch: Is Biohaven Ltd on track to beat earnings2026 EndofMonth & High Win Rate Trade Alerts - baoquankhu1.vn
Valuation Update: What are analysts price targets for Biohaven LtdMarket Sentiment Review & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Biohaven Ltd. ($BHVN) CEO 2025 Pay Revealed - Quiver Quantitative
Integral Health Asset Management LLC Buys 350,000 Shares of Biohaven Ltd. $BHVN - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Biohaven Ltd. (BHVN), Allogene Therapeutics (ALLO) - The Globe and Mail
Biohaven (NYSE: BHVN) outlines R&D pipeline and 2026 shareholder votes - Stock Titan
Capital Research Global Investors Raises Position in Biohaven Ltd. $BHVN - MarketBeat
Capital Research Global Investors Boosts Stake in Biohaven - National Today
Macro Review: Is Biohaven Ltd gaining market shareWeekly Trading Summary & Technical Entry and Exit Tips - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Biohaven Ltd. (BHVN) and Siemens Healthineers AG (OtherSEMHF) - The Globe and Mail
TD Cowen Boosts Biohaven (NYSE:BHVN) Price Target to $30.00 - MarketBeat
Analysts Have Conflicting Sentiments on These Healthcare Companies: Dyne Therapeutics (DYN), Biohaven Ltd. (BHVN) and Teladoc (TDOC) - The Globe and Mail
Assessing Biohaven (BHVN) Valuation After Pipeline Optimism And Supportive Sector Sentiment - simplywall.st
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Why Biohaven (BHVN) Is Down 13.5% After Narrower Losses And A New Share Shelf Registration - simplywall.st
Raymond James Maintains Strong Buy on Biohaven Ltd. (BHVN) March 2026 - Meyka
Biohaven (BHVN) director trust purchase corrected to 28,400 shares - Stock Titan
Raymond James reiterates Strong Buy on Biohaven stock after competitor data - Investing.com Australia
Raymond James reiterates Strong Buy on Biohaven stock after competitor data By Investing.com - Investing.com South Africa
Biohaven Reports Q4 EPS Beat Expectations, Plans Stock Issuance - Intellectia AI
Biohaven (NYSE:BHVN) Shares Gap UpTime to Buy? - MarketBeat
Biohaven Ltd stock whipsaws after FDA exit revives rare-disease bets - Bez Kabli
What's Going On With Biohaven Stock On Monday? - Benzinga
Breakout Watch: Can Biohaven Ltd stock outperform in a bear marketJuly 2025 PostEarnings & Risk Managed Trade Strategies - baoquankhu1.vn
Death Cross: Is Biohaven Ltd a stock for growth or value investors2025 Winners & Losers & Reliable Trade Execution Plans - baoquankhu1.vn
Technical Reactions to BHVN Trends in Macro Strategies - Stock Traders Daily
TD Asset Management Inc Cuts Stake in Biohaven Ltd. $BHVN - MarketBeat
Biohaven stock price target lowered to $10 by H.C. Wainwright - Investing.com South Africa
Biohaven (NYSE:BHVN) Given New $10.00 Price Target at HC Wainwright - MarketBeat
BHVN Earnings History & Surprises | EPS & Revenue Results | BIOHAVEN LTD (NYSE:BHVN) - ChartMill
BHVN: HC Wainwright & Co. Lowers Price Target While Maintaining - GuruFocus
Biohaven Ltd Stock (BHVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.33%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):